Literature DB >> 27939125

Radiologic Response Assessment in Pediatric Soft Tissue Sarcoma: Computed-Assisted Volume Evaluation.

Giovanna Orsatti1, Valeria Beltrame2, Filippo Crimì2, Anna Chiara Frigo3, Gianni Bisogno4, Roberto Stramare2.   

Abstract

OBJECTIVES: To compare 3 methods of dimensional assessment, with particular attention to a new software assisted method of volume calculation, in soft tissue sarcoma, and to investigate the interobserver agreement and the intermethod agreement in chemotherapy response classification and resultant clinical repercussions. STUDY
DESIGN: We studied 34 pediatric patients with nonmetastatic soft tissue sarcoma who had undergone only diagnostic biopsy. Tumor size was measured both at diagnosis and after induction chemotherapy by 3 observers and using 3 measurement methods: maximum axis (1 diameter), estimated volume (3 diameters), and computed volume (software-assisted volume calculation). We used overall concordance correlation coefficient and Bland-Altman statistical methods to assess interobserver agreement and overall concordance correlation coefficient and the κ Cohen coefficient to assess intermethod agreement.
RESULTS: According to overall concordance correlation coefficient, the interobserver agreement was very high for each method, with a slight superiority of the software assisted method; this agreement was not confirmed in Bland-Altman plots for maximum axis and estimated volume methods. According to kappa coefficients, the intermethod agreement in chemotherapy response evaluation was poor.
CONCLUSIONS: Computed volume was the most accurate method in soft tissue sarcoma tumor size assessment. One- and 3-dimensional methods are not concordant in chemotherapy response classification. In particular, the maximum axis method underestimates chemotherapy response and can lead to switching the chemotherapy regimen erroneously.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  pediatric; sarcoma; tumor; volume

Mesh:

Year:  2016        PMID: 27939125     DOI: 10.1016/j.jpeds.2016.11.040

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  2 in total

1.  Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.

Authors:  Theodore W Laetsch; Steven G DuBois; Leo Mascarenhas; Brian Turpin; Noah Federman; Catherine M Albert; Ramamoorthy Nagasubramanian; Jessica L Davis; Erin Rudzinski; Angela M Feraco; Brian B Tuch; Kevin T Ebata; Mark Reynolds; Steven Smith; Scott Cruickshank; Michael C Cox; Alberto S Pappo; Douglas S Hawkins
Journal:  Lancet Oncol       Date:  2018-03-29       Impact factor: 41.316

2.  GEIS-SEHOP clinical practice guidelines for the treatment of rhabdomyosarcoma.

Authors:  S Gallego; D Bernabeu; M Garrido-Pontnou; G Guillen; N Hindi; A Juan-Ribelles; C Márquez; C Mata; J Orcajo; G Ramírez; M Ramos; C Romagosa; D Ruano; P Rubio; R Vergés; C Valverde
Journal:  Clin Transl Oncol       Date:  2021-07-01       Impact factor: 3.405

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.